| 30/09/26 | 13:00:00 | 30 Sept 2026 | | Interim Results for the Six Months to June 30, 2026, and Business Update | GNW |
| 25/09/26 | 07:00:00 | 25 Sept 2026 | | The FOCUS-01 Clinical Trial Design and Preclinical Data Further Demonstrate the Potential of AVA6103 at AACR Conference on Pancreatic Cancer | GNW |
| 16/09/26 | 16:00:00 | 16 Sept 2026 | | Avacta Achieves Clinical Proof of Mechanism for the Next Generation of pre|CISION® Medicines with AVA6103 (FAP-Exd) in the Phase 1 FOCUS-01 Trial | GNW |
| 14/09/26 | 07:00:00 | 14 Sept 2026 | | Avacta Appoints Mats Blom to the Board of Directors as Chair of Audit Committee | GNW |
| 08/07/26 | 07:00:00 | 8 Jul 2026 | | Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors | GNW |
| 01/06/26 | 07:00:00 | 1 Jun 2026 | | Avacta presents updated clinical data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at ASCO 2026 | GNW |
| 19/05/26 | 07:14:00 | 19 May 2026 | | Unaudited Preliminary Results for the Year Ended December 31, 2025 | GNW |
| 06/05/26 | 07:00:00 | 6 May 2026 | | Avacta presents new comparisons of pre|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026 | GNW |
| 21/04/26 | 17:00:00 | 21 Apr 2026 | | Avacta data at AACR 2026 underline favorable profile of AVA6103 and advantages of pre|CISION® delivery platform | GNW |
| 23/06/22 | 16:27:30 | 23 Jun 2022 | | Result of Annual General Meeting | RNS |
| 16/06/22 | 16:41:02 | 16 Jun 2022 | | Second Price Monitoring Extn | RNS |
| 16/06/22 | 16:36:14 | 16 Jun 2022 | | Price Monitoring Extension | RNS |
| 31/05/22 | 07:00:06 | 31 May 2022 | | Posting of Annual Report and Notice of AGM | RNS |
| 16/05/22 | 12:00:07 | 16 May 2022 | | AffyXell expands partnership with GenScript ProBio | RNS |
| 11/05/22 | 07:00:05 | 11 May 2022 | | London Therapeutics headquarters established | RNS |
| 06/05/22 | 07:00:07 | 6 May 2022 | | Block Listing Application to AIM (update) | RNS |
| 28/04/22 | 13:53:19 | 28 Apr 2022 | | Block Listing Application to AIM | RNS |
| 14/04/22 | 17:01:03 | 14 Apr 2022 | | Issue of Equity and Total Voting Rights | RNS |
| 14/04/22 | 11:29:20 | 14 Apr 2022 | | Issue of Equity and Total Voting Rights | RNS |
| 13/04/22 | 07:00:10 | 13 Apr 2022 | | AffyXell milestone and increased equity stake | RNS |
| 12/04/22 | 07:00:05 | 12 Apr 2022 | | Poster presented at the AACR available to download | RNS |
| 11/04/22 | 16:41:24 | 11 Apr 2022 | | Second Price Monitoring Extn | RNS |
| 11/04/22 | 16:35:32 | 11 Apr 2022 | | Price Monitoring Extension | RNS |
| 11/04/22 | 14:05:44 | 11 Apr 2022 | | Second Price Monitoring Extn | RNS |
| 11/04/22 | 14:00:58 | 11 Apr 2022 | | Price Monitoring Extension | RNS |
| 08/04/22 | 13:57:24 | 8 Apr 2022 | | Issue of Equity and Total Voting Rights | RNS |
| 08/04/22 | 07:00:04 | 8 Apr 2022 | | AffyXell partners with Biocytogen and KNTSC | RNS |
| 07/04/22 | 16:31:15 | 7 Apr 2022 | | Issue of Equity and Total Voting Rights | RNS |
| 06/04/22 | 07:00:07 | 6 Apr 2022 | | Preliminary Results | RNS |
| 30/03/22 | 16:41:09 | 30 Mar 2022 | | Second Price Monitoring Extn | RNS |
| 30/03/22 | 16:35:49 | 30 Mar 2022 | | Price Monitoring Extension | RNS |
| 30/03/22 | 07:00:06 | 30 Mar 2022 | | Notice of Results and Investor Presentation | RNS |
| 29/03/22 | 07:00:09 | 29 Mar 2022 | | AVA6000 data poster presentation at AACR | RNS |
| 21/03/22 | 07:00:10 | 21 Mar 2022 | | Directorate Change | RNS |
| 16/03/22 | 07:00:04 | 16 Mar 2022 | | Vimian acquires Avacta’s Animal Health Division | RNS |
| 14/02/22 | 16:41:25 | 14 Feb 2022 | | Second Price Monitoring Extn | RNS |
| 14/02/22 | 16:36:05 | 14 Feb 2022 | | Price Monitoring Extension | RNS |
| 07/02/22 | 16:36:06 | 7 Feb 2022 | | Price Monitoring Extension | RNS |
| 03/02/22 | 17:26:49 | 3 Feb 2022 | | Issue of Equity and Total Voting Rights | RNS |
| 03/02/22 | 16:41:17 | 3 Feb 2022 | | Second Price Monitoring Extn | RNS |
| 03/02/22 | 16:35:45 | 3 Feb 2022 | | Price Monitoring Extension | RNS |
| 03/02/22 | 07:00:04 | 3 Feb 2022 | | Dose escalation in the phase I trial of AVA6000 | RNS |
| 31/01/22 | 16:41:19 | 31 Jan 2022 | | Second Price Monitoring Extn | RNS |
| 31/01/22 | 16:36:22 | 31 Jan 2022 | | Price Monitoring Extension | RNS |
| 18/01/22 | 07:00:06 | 18 Jan 2022 | | Second pre|CISION Pro-drug Candidate Selected | RNS |
| 12/01/22 | 14:05:33 | 12 Jan 2022 | | Second Price Monitoring Extn | RNS |
| 12/01/22 | 14:00:27 | 12 Jan 2022 | | Price Monitoring Extension | RNS |
| 10/01/22 | 07:00:09 | 10 Jan 2022 | | Update on AffiDX and detection of Omicron variant | RNS |
| 04/01/22 | 11:06:14 | 4 Jan 2022 | | Second Price Monitoring Extn | RNS |
| 04/01/22 | 11:01:02 | 4 Jan 2022 | | Price Monitoring Extension | RNS |
